Literature DB >> 32145867

Amyloidosis as a Systemic Disease in Context.

Sarah A M Cuddy1, Rodney H Falk2.   

Abstract

The systemic amyloidoses are a group of diseases characterized by the deposition of amyloid, a material formed from misfolding of proteins, in one or more organs. The 2 commonest forms of amyloidosis are transthyretin amyloidosis (ATTR), derived from wild-type or mutant transthyretin, and light-chain (AL) amyloidosis, derived from abnormal circulating light chains produced by plasma cell dyscrasia. Both frequently involve the heart, producing an infiltrative cardiomyopathy with restrictive pathophysiology. Although advances in echocardiographic, magnetic resonance, and nuclear imaging have rendered diagnosis of cardiac amyloidosis easier, diagnosis is still often delayed. This review focuses on noncardiac manifestations of AL and TTR amyloidosis that may aid the cardiologist in making an earlier diagnosis of cardiac amyloidosis in a patient with cardiac symptoms (such as periorbital purpura in AL amyloidosis and a history of carpal tunnel syndrome and ruptured biceps tendon in ATTR). It also focuses on the unique challenges that treatment of cardiac amyloidosis poses owing to concomitant noncardiac disease, such as nephrotic syndrome-related edema and hypotension due to autonomic neuropathy, and stresses the importance of a precise typing of amyloidosis and a multidisciplinary approach to therapy.
Copyright © 2020 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32145867     DOI: 10.1016/j.cjca.2019.12.033

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  7 in total

1.  Huntington's disease: lessons from prion disorders.

Authors:  Melanie Alpaugh; Francesca Cicchetti
Journal:  J Neurol       Date:  2021-02-24       Impact factor: 4.849

Review 2.  Cardiac amyloidosis-interdisciplinary approach to diagnosis and therapy.

Authors:  A Hänselmann; D Berliner; J Bauersachs; U Bavendiek
Journal:  Herz       Date:  2022-06-08       Impact factor: 1.740

Review 3.  Genetic Insights into Primary Restrictive Cardiomyopathy.

Authors:  Andreas Brodehl; Brenda Gerull
Journal:  J Clin Med       Date:  2022-04-08       Impact factor: 4.964

4.  Lung cancer combined with diffuse peritoneal and mesenteric amyloidosis detected on 18F-FDG PET/CT: A case report.

Authors:  JianJie Wang; Bin Zhao; Tianbin Song; Jidong Sun
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

Review 5.  ATTR Epidemiology, Genetics, and Prognostic Factors.

Authors:  Chukwuemeka A Obi; William C Mostertz; Jan M Griffin; Daniel P Judge
Journal:  Methodist Debakey Cardiovasc J       Date:  2022-03-14

6.  Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data.

Authors:  Nicholas J Viney; Shuling Guo; Li-Jung Tai; Brenda F Baker; Mariam Aghajan; Shiangtung W Jung; Rosie Z Yu; Sheri Booten; Heather Murray; Todd Machemer; Sebastien Burel; Sue Murray; Gustavo Buchele; Sotirios Tsimikas; Eugene Schneider; Richard S Geary; Merrill D Benson; Brett P Monia
Journal:  ESC Heart Fail       Date:  2020-12-07

Review 7.  Subclinical cardiac damage in cancer patients before chemotherapy.

Authors:  Iacopo Fabiani; Giorgia Panichella; Alberto Aimo; Chrysanthos Grigoratos; Giuseppe Vergaro; Nicola Riccardo Pugliese; Stefano Taddei; Daniela Maria Cardinale; Claudio Passino; Michele Emdin; Alberto Giannoni
Journal:  Heart Fail Rev       Date:  2021-07-27       Impact factor: 4.654

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.